ChAdOx1nCoV-19 vaccination

ChAd0x1 nCoV-19 (AZD 1222) is the main vaccine that is planned to roll-out in Thailand and involve vaccinating people especially in high-risk categories. This vaccine is contained in the multiple-dose vial for vaccinating 10 recipients for 0.5 mL each. However, the additional volume of vaccine was overfilled to 6.5 mL per vial which the vaccination can be administered to more than 10 doses. The University Hospital Network (UHOSNET) and Faculty of Medicine Vajira Hospital, Navamindradhiraj University have jointly stipulated the preparation and vaccination of ChAdox1 – n CoV-19 vaccine with 12 doses per vial injection with traditional 21 or 24 G needle. Taken together, we planned to investigate the immune response of participants after first dose of ChAd0x1 nCoV-19 vaccination with such techniqueChAd0x1新型冠状病毒（ChAd0x1 nCoV-19，AZD 1222）疫苗是泰国计划推广的核心疫苗，主要用于人群接种，重点覆盖高风险群体。该疫苗采用多剂量瓶包装，常规情况下每瓶可供10名受种者接种，每人接种剂量为0.5mL。但该疫苗实际采用超量灌装，每瓶灌装量达6.5mL，因此单瓶可提供的接种剂次超过10剂。大学医院网络（University Hospital Network，UHOSNET）与纳瓦明德拉吉大学医学院瓦集拉医院联合制定了该疫苗的配制与接种规程：采用传统21G或24G针头，单瓶接种12剂次。基于上述背景，本研究计划探究采用该接种方案完成首剂ChAd0x1新型冠状病毒疫苗接种后，受试者的免疫应答情况。